z-logo
Premium
Feasibility of evaluating Crohn's disease activity at 3.0 Tesla
Author(s) -
van GemertHorsthuis Karin,
Florie Jasper,
Hommes Daniel W.,
Lavini MPhil Cristina,
Reitsma Johannes B.,
van Deventer Sander J.,
Stoker Jaap
Publication year - 2006
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.20650
Subject(s) - grading (engineering) , radiological weapon , medicine , crohn's disease , radiology , nuclear medicine , magnetic resonance imaging , crohn disease , disease , engineering , civil engineering
Purpose To determine whether abdominal 3.0T MRI can be used for evaluation of Crohn's disease (CD) compared with ileocolonoscopy (CS), and to determine patient preference for MRI as opposed to CS. Materials and Methods Twenty patients scheduled for CS underwent MRI. At CS, disease severity was graded and the Crohn's Disease Endoscopic Index of Severity (CDEIS) was determined. Radiological grading (by two observers) was compared with endoscopic grading and CDEIS. Patient experience and preference were determined. Results In respectively 10 (observer 1) and 13 patients (observer 2) exact agreement between radiological and endoscopic grading was found. In respectively 10 and 7 patients radiological and endoscopic grading differed one level. No statistically significant correlation was found between radiological grading and CDEIS. Between bowel wall thickness and CDEIS weak to moderate correlations were found, and between bowel wall enhancement and CDEIS weak correlations were found. All patients preferred MRI over CS. Conclusion It is feasible to perform abdominal 3.0T MRI using orally administered contrast medium for evaluation of CD, and this method can be considered a patient‐friendly alternative to CS. J. Magn. Reson. Imaging 2006. © 2006 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here